Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ1062 plus fulvestrant vs placebo plus fulvestrant in HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alterations
CTR20254562Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NTQ1062 in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2026; status: active.
02
Drugs
NTQ1062
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254562.